An Overview of Neurological and Psychiatric Complications During Post-COVID Period: A Narrative Review
Dan Li,Qiang Wang,Chengyou Jia,Zhongwei Lv,Jianshe Yang
DOI: https://doi.org/10.2147/jir.s375494
IF: 4.5
2022-07-26
Journal of Inflammation Research
Abstract:Dan Li, 1, 2 Qiang Wang, 3 Chengyou Jia, 1 Zhongwei Lv, 1 Jianshe Yang 1, 3 1 Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, People's Republic of China; 2 Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China; 3 Basic Medical School, Gansu Medical College, Pingliang, 744000, People's Republic of China Correspondence: Jianshe Yang, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, People's Republic of China, Tel/Fax +86-21-66302721, Email The coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a multi-organ and multi-system disease with high morbidity and mortality in severe cases due to respiratory failure and severe cardiovascular events. However, the various manifestations of neurological and psychiatric (N/P) systems of COVID-19 should not be neglected. Some clinical studies have reported a high risk of N/P disorders in COVID-19 and post-COVID-19 patients and that their outcomes were positively associated with the disease severity. These clinical manifestations could attribute to direct SARS-CoV-2 invasion into the central nervous system (CNS), which is often complicated by systemic hypoxia, the dysfunctional activity of the renin–angiotensin system and other relevant pathological changes. These changes may remain long term and may even lead to persistent post-COVID consequences on the CNS, such as memory, attention and focus issues, persistent headaches, lingering loss of smell and taste, enduring muscle aches and chronic fatigue. Mild confusion and coma are serious adverse outcomes of neuropathological manifestations in COVID-19 patients, which could be diversiform and vary at different stages of the clinical course. Although lab investigations and neuro-imaging findings may help quantify the disease's risk, progress and prognosis, large-scale and persistent multicenter clinical cohort studies are needed to evaluate the impact of COVID-19 on the N/P systems. However, we used "Boolean Operators" to search for relevant research articles, reviews and clinical trials from PubMed and the ClinicalTrials dataset for "COVID-19 sequelae of N/P systems during post-COVID periods" with the time frame from December 2019 to April 2022, only found 42 in 254,716 COVID-19-related articles and 2 of 7931 clinical trials involved N/P sequelae during post-COVID periods. Due to the increasing number of infected cases and the incessant mutation characteristics of this virus, diagnostic and therapeutic guidelines for N/P manifestations should be further refined. Keywords: COVID-19, neurological, post-COVID, psychiatric, SARS-CoV-2, sequelae The coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a multi-organ and multi-system disease 1 and a global pandemic, with more than 500 million confirmed cases and 6 million deaths. COVID-19 has high morbidity because the SARS-CoV-2, especially its latest Omicron variant, 2 is highly infectious, can be transmitted via multiple routes and has high mortality in severe cases due to respiratory failure and lethal cardiovascular events. 3,4 As the neurological system is susceptible to SARS-CoV-2 infection, 5–7 the various manifestations of neurological and psychiatric (N/P) systems during its acute and subsequent phases should not be neglected. Clinical studies reported a high risk of N/P disorders in COVID-19 and post-COVID-19 patients and also found that their outcomes were positively associated with the severity of COVID-19. 8–10 These clinical manifestations occur due to the direct invasion of SARS-CoV-2 into the central nervous system (CNS), often complicated by systemic hypoxia, dysfunctional activity of the renin–angiotensin system and other relevant pathological changes. These changes may remain long term and persistently causing post-COVID-19 CNS-related symptoms such as difficulties in memory, attention and focus, persistent headaches, lingering loss of sense of smell and taste, enduring muscle aches and chronic fatigue. Mild confusion and coma are among the most serious adverse outcomes of the neuropathological manifestations in COVID-19 patients. 11,12 N/P manifestations in COVID-19 patients are diversiform and vary at different stages of their clinical course. Though lab investigations and neuro-imaging findings are helpful in quantifying the disease progress and patients' risks and prognosis, large-scale and persistent multicenter clinical cohort studies are needed to evaluate the impact and interaction of COVID-19 on the N/P systems. Due to the increasing populati -Abstract Truncated-
immunology